Read by QxMD icon Read

Human Psychopharmacology

Vlasios Brakoulias, Vladan Starcevic, Umberto Albert, Shyam Sundar Arumugham, Brenda E Bailey, Amparo Belloch, Tania Borda, Liliana Dell'Osso, Jason A Elias, Martha J Falkenstein, Ygor A Ferrao, Leonardo F Fontenelle, Lena Jelinek, Leto Kalogeraki, Brian Kay, Luana D Laurito, Christine Lochner, Giuseppe Maina, Donatella Marazziti, Andrew Martin, Hisato Matsunaga, Euripedes C Miguel, Pedro Morgado, Irakis Mourikis, Massimo Pasquini, Rodrigo Perez Rivera, Sriramya Potluri, Janardhan Y C Reddy, Brian C Riemann, Maria Conceição do Rosario, Roseli G Shavitt, Dan J Stein, Kirupumani Viswasam, Zhen Wang, Naomi A Fineberg
OBJECTIVE: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive-compulsive disorder (OCD). METHODS: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. RESULTS: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants...
January 10, 2019: Human Psychopharmacology
Anastasia Levchenko, Natalya Vyalova, Ivan V Pozhidaev, Anastasiia S Boiko, Diana Z Osmanova, Olga Yu Fedorenko, Arkadiy V Semke, Nikolay A Bokhan, Bob Wilffert, Anton J M Loonen, Svetlana A Ivanova
OBJECTIVE: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. METHODS: DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi-squared tests and analyses of variance...
January 8, 2019: Human Psychopharmacology
Rainer Schneider, Nick Singer, Tim Singer
OBJECTIVE: According to a series of recent meta-analyses and systematic reviews, aromatherapy has shown to be effective in treating patients with different medical conditions. However, many of the clinical studies are of rather low methodological quality. Moreover, there is much conceptual ambiguity with regard to what aromatherapy actually constitutes. METHOD: In this paper, we discuss the conditions under which aromatherapy is most likely to be of medical value by outlining the workings of the olfactory system and the necessary requirements of odors to be therapeutic...
December 7, 2018: Human Psychopharmacology
Efthymios Hadjis, Molly Hyde, Joelle Choueiry, Natalia Jaworska, Renee Nelson, Sara de la Salle, Dylan Smith, Rob Aidelbaum, Verner Knott
OBJECTIVE: The effects of GABA modulating drugs and nicotine, the prototypical nicotinic cholinergic agonist, on attention have been investigated using subcomponents of the P300 event-related potentials (ERP), which index involuntary (P3a) and voluntary attention (P3b). However, investigations into how such pharmacologic effects interact with genetic features in the GABA system remain unclear. This study examined the moderating effects of a single nucleotide polymorphism (rs7557793) in the glutamic acid decarboxylase 67 (GAD1) gene, which is implicated in the conversion of glutamate to GABA, on P300-indices of auditory attentional processing; the influence of nicotine administration was also assessed...
November 29, 2018: Human Psychopharmacology
Masakazu Hatano, Hiroyuki Kamei, Ippei Takeuchi, Kaori Tozawa, Shinya Makino, Manako Hanya, Shigeki Yamada, Nakao Iwata
OBJECTIVE: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. METHODS: This was a case-control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period...
November 27, 2018: Human Psychopharmacology
Marco Calabrò, Chiara Fabbri, Concetta Crisafulli, Diego Albani, Gianluigi Forloni, Siegfried Kasper, Antonina Sidoti, Elvira Velardi, Joseph Zohar, Alzbeta Juven-Wetzler, Daniel Souery, Stuart Montgomery, Julien Mendlewicz, Alessandro Serretti
No abstract text is available yet for this article.
November 13, 2018: Human Psychopharmacology
Yoshiyuki Tsuruta, Kunihiro Iwamoto, Masahiro Banno, Naoko Kawano, Kunihiro Kohmura, Seiko Miyata, Hiroshige Fujishiro, Yukihiro Noda, Akiko Noda, Shuji Iritani, Norio Ozaki
OBJECTIVE: To assess the effects of hypnotics on prefrontal cortex activity in healthy subjects using near-infrared spectroscopy (NIRS) in a double-blind, placebo-controlled crossover trial. METHODS: Eighteen healthy males received acute doses of ramelteon (8 mg), triazolam (0.125 mg), or placebo in a predetermined randomization schedule, with a washout period of more than 1 week. All subjects performed a verbal fluency task during NIRS assessments at baseline and at 1 and 4 hr post-dose...
October 25, 2018: Human Psychopharmacology
Michael S Zastrozhin, Aleksandr S Sorokin, Tatyana V Agibalova, Elena A Grishina, Anastasiya Р Antonenko, Ilya N Rozochkin, Denis V Duzhev, Valentine Y Skryabin, Tatyana E Galaktionova, Ilya V Barna, Anna V Orlova, Albert D Aguzarov, Ludmila M Savchenko, Evgeny A Bryun, Dmitry A Sychev
INTRODUCTION: Although pharmacogenetic tests provide the information on a genotype and the predicted phenotype, these tests themselves do not provide the interpretation of data for a physician. There are currently approximately two dozen pharmacogenomic clinical decision support systems used in psychiatry. Implementation of clinical decision support systems capable of forming recommendations on drug and dose selection according to the results of pharmacogenetic testing is an urgent task...
October 25, 2018: Human Psychopharmacology
Patrick C Dolder, Elizabeth B de Sousa Fernandes Perna, Natasha L Mason, Nadia R P W Hutten, Stefan W Toennes, Eef L Theunissen, Johannes G Ramaekers, Kim P C Kuypers
OBJECTIVES: 4-Fluoroamphetamine (4-FA) is a novel psychoactive substance with a pharmacological profile and reported subjective effects (e.g., empathy) intermediate between 3,4-methylenedioxymethamphetamine (MDMA) and amphetamine. Studies have shown that MDMA and amphetamine increase emotional empathy without affecting cognitive empathy; MDMA simultaneously leads to elevated levels of oxytocin, unrelated to its behavioral effects. The aim of the present study was to assess the reported enhancement of empathy by 4-FA, to assess its effects on oxytocin, and to test potential associations between both...
October 25, 2018: Human Psychopharmacology
Oliver G Bosch, Fabrizio Esposito, Dario Dornbierer, Robin von Rotz, Rainer Kraehenmann, Philipp Staempfli, Boris B Quednow, Erich Seifritz
OBJECTIVE: Gamma-hydroxybutyrate (GHB) is an endogenous GHB-/GABA-B receptor agonist and a narcolepsy treatment. However, GHB is also abused for its prohedonic effects. On a neuronal level, it was shown that GHB increases regional cerebral blood flow in limbic areas such as the right anterior insula (rAI) and the anterior cingulate cortex (ACC). We aimed to further explore the association between the subjective and neuronal signatures of GHB. METHOD: We assessed subjective effects and resting-state functional connectivity (rsFC) of an rAI- and an ACC-seed in 19 healthy male subjects after GHB (35 mg/kg p...
November 2018: Human Psychopharmacology
Laura Musetti, Antonio Tundo, Alessandra Benedetti, Gabriele Massimetti, Erika Cambiali, Irene Pergentini, Claudia Del Grande, Liliana Dell'Osso
OBJECTIVE: This study aims to describe the prescription patterns of the mood stabilizers most commonly used for the treatment of bipolar I and II disorders (lithium, valproate, and carbamazepine) and to analyze the treatment outcomes. METHODS: Two hundred and thirty-four outpatients with bipolar disorders receiving prophylactic treatment with lithium, valproate, carbamazepine, or their combination were followed up for at least 18 months in two Italian psychiatric centers specialized in mood disorders...
October 12, 2018: Human Psychopharmacology
Merve Demirbugen Oz, Zuhal Uckun, Nazan Yuce-Artun, Bora Baskak, Hatice Ozdemir, Tugba Kizil Ozel, Halise Devrimci Ozguven, H Sinan Suzen
OBJECTIVE: The aim of the present study was to determine the relationship between the polymorphisms of -1438A/G and 102T/C in the 5-HT2A receptor (HTR2A) gene and nausea/vomiting as a side effect induced by sertraline (SERT) or citalopram (CIT) in patients with major depressive disorder. METHODS: A total of 128 patients were enrolled, 63 patients received CIT, whereas 65 patients were treated with SERT. Nausea/vomiting were assessed with the UKU Side-effects Rating Scale at baseline and at the end of the second and fourth weeks...
September 17, 2018: Human Psychopharmacology
Ndaba Mazibuko, Mitul A Mehta
OBJECTIVE: Recent efforts to optimise translation of basic research findings to successful clinical trials have led to a sharper focus on experimental medicine translational studies. This is coupled with a movement towards greater methodological integrity and openness. Although this can be achieved through preregistration and detailed reporting of study methodology, the reality of study application can often be lost. METHODS: In practice, challenges in study application can often lead to diminished scientific robustness, even in well-designed studies...
September 2018: Human Psychopharmacology
Peter van Ruitenbeek, Dennis Hernaus, Mitul Ashok Mehta
OBJECTIVE: Cognitive deficits including impaired working memory are a hallmark feature of schizophrenia. Dopamine D1 receptor modulated changes in prefrontal cortex function play a potentially important role in the pathology underlying such deficits. However, pharmacological interventions that selectively engage the D1 receptor are severely restricted for research in humans. The present study is a proof-of-principle for enhancing cognitive performance and associated brain activation via indirect D1 stimulation, operationalised by combining the nonselective dopamine agonist L-dopa with the D2-antagonist haloperidol...
September 2018: Human Psychopharmacology
Amanda J Lisoway, Gwyneth Zai, Arun K Tiwari, Clement C Zai, Karen Wigg, Vanessa Goncalves, Danning Zhang, Natalie Freeman, Daniel J Müller, James L Kennedy, Margaret A Richter
OBJECTIVES: A recent genome-wide association study (GWAS) in obsessive-compulsive disorder (OCD) reported a significant marker in the dispatched homolog 1 (Drosophila) gene (DISP1 gene) associated with serotonin reuptake inhibitor (SRI) antidepressant response (Qin et al., ). DISP1 has never been examined before in terms of association with SRI response until this GWAS. We attempt to replicate the GWAS finding by investigating the association of the DISP1 rs17162912 polymorphism with SRI response in our sample of 112 European Caucasian OCD patients...
July 2018: Human Psychopharmacology
Robert Ross MacLean, Andrew J Waters, Emily Brede, Mehmet Sofuoglu
OBJECTIVE: Drugs that enhance cholinergic transmission have demonstrated promise treating addictive disorders. Galantamine, an acetylcholinesterase inhibitor, may reduce cigarette smoking in otherwise healthy treatment-seeking smokers. METHODS: The current study is a double-blind, placebo-controlled, study that randomized daily smokers (n = 60) to receive one of two doses of galantamine extended release (8 or 16 mg/day), or a placebo treatment. Participants completed a smoking choice task as well as study measures and cognitive tasks in the laboratory and daily life using ecological momentary assessment...
July 2018: Human Psychopharmacology
Alireza Ghajar, Faezeh Gholamian, Maryam Tabatabei-Motlagh, Mohsen Afarideh, Farzin Rezaei, Maryam Ghazizadeh-Hashemi, Shahin Akhondzadeh
OBJECTIVE: We aimed to evaluate the efficacy and tolerability of citicoline add-on therapy in treatment of negative symptoms in patients with stable schizophrenia. METHODS: In a double-blind and placebo-controlled study, patients with stable schizophrenia (DSM-5) were randomized to receive either 2,500 mg/day citicoline or placebo in addition to risperidone for 8 weeks. The patients were assessed using the positive and negative syndrome scale (PANSS), the extrapyramidal symptom rating scale (ESRS), and Hamilton depression rating scale (HDRS)...
July 2018: Human Psychopharmacology
Ashley N Linden-Carmichael, Amy L Stamates, Cecile A Marczinski, Cathy Lau-Barraco
No abstract text is available yet for this article.
July 2018: Human Psychopharmacology
Andrew Scholey, Sarah Benson, Sean Johnson, Chris Alford, Samuel Benrejeb Godefroy, Joris C Verster
No abstract text is available yet for this article.
July 2018: Human Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"